

KURZPROTOKOLL
OLE NEAT

Öffentlicher Titel	Phase-3-Studie zu EryDex bei Patienten mit Louis-Bar-Syndrom nach Teilnahme an der Studie IEDAT-04-2022
Wissenschaftl. Titel	An Open-Label Extension Study of EryDex in Patients with Ataxia Teleangiectasia Following Participation in Study IEDAT-04-2022 (OLE NEAT)
Kurztitel	OLE NEAT
Studienart	multizentrisch, prospektiv, Therapiestudie, offen/unverblindet, einarmig, Pharma-Studie
Studienphase	Phase III
Erkrankung	Kinder: sonstige
Einschlusskriterien	- body weight 15 kg - participation in IEDAT-04-2022 study and its completion, including final efficacy and safety assessments
Ausschlusskriterien	- safety contraindications for continuation of treatment, as determined by the investigator - clinically significant immune impairment that, in the opinion of the Investigator, precludes further treatment with corticosteroids - Current neoplastic disease or previous neoplastic disease not in remission for at least 2 years. - requiring treatment with a systemic corticosteroid
Alter	>= 6 Jahre
Sponsor	Quince Therapeutics S.p.A.
Registrierung in anderen Studienregistern	EUCT 2024-513618-37-00 ClinicalTrials.gov NCT06664853
Links	Zu den Ein- und Ausschlusskriterien